Op-Eds Reform FDA advisory committees and put rare disease patients first Tricia Flanagan · June 11, 2026 11:00 am
Op-Eds Fifty years of modern biotech, and an appetite for change Abe Sinay-Smith · June 8, 2026 10:00 am
Healthcare FDA launches mifepristone study after pressure from Trump’s right flank Rena Rowe · June 5, 2026 11:55 am
Op-Eds It’s time for Congress to end Big Pharma’s war on generics David Marin · June 4, 2026 11:00 am
Op-Eds States already have pharmacy deserts. PBM reforms make it worse Naomi Lopez · June 3, 2026 10:00 am
Op-Eds The FDA is moving faster on psychedelics — now Washington must do more Peter Pitts · June 3, 2026 9:00 am
Op-Eds To fight the drug affordability crisis, Trump must crack down on middlemen Carl Schmid · June 3, 2026 6:00 am
Op-Eds Treatment for millions of Americans at stake in ‘skinny label’ Supreme Court case Kristina Acri · June 2, 2026 8:00 am
Op-Eds
